Telix Pharmaceuticals Ltd 2023 SR
The report outlines Telix Pharmaceuticals' sustainability progress in 2023 across its five pillars: Purpose, People, Principles, Performance, and Planet. Key highlights include the global expansion of its diagnostic product Illuccix, the launch of early access programs for Zircaix, and the implementation of a student bursary scheme in regional Australia. The company focused on establishing a baseline for Scope 1 and 2 emissions and aligned its climate disclosures with TCFD and ISSB standards. Additionally, Telix emphasized diversity, with women representing 49% of the global workforce and 33% of the Board.
Company: Telix Pharmaceuticals Ltd
Sector: Health Care
Country: Australia
Year: 2023
Type: SR
Pages: 17
Telix Pharmaceuticals Ltd
Sustainability Report
The report outlines Telix Pharmaceuticals' sustainability progress in 2023 across its five pillars: Purpose, People, Principles, Performance, and Planet. Key highlights include the global expansion of its diagnostic product Illuccix, the launch of early access programs for Zircaix, and the implementation of a student bursary scheme in regional Australia. The company focused on establishing a baseline for Scope 1 and 2 emissions and aligned its climate disclosures with TCFD and ISSB standards. Additionally, Telix emphasized diversity, with women representing 49% of the global workforce and 33% of the Board.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
2023
Fiscal Year
2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management